Visit

2 Feb

2021

The Roivant Sciences dealmaking strategy revolutionising life sciences IP monetisation

The trail-blazing biopharma company has pioneered a new model for monetising patents, setting important precedents for industry dealmaking

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth

TAGS

Patents, Strategy, Technology Licensing, Transactions, Valuation, Life Sciences, Japan, North America, United States of America

Twitter

25 Feb 2021

@IAM_Alerts Potentially very big news - the IEEE is reviewing its controversial patent policy, six years after it was changed i… https://t.co/yRnFwbX8Cl Read more

25 Feb 2021

@IAM_Alerts Given new opportunities for monetisation, entities involved in healthcare research must have a strategy for protect… https://t.co/BG93bhHxyU Read more

25 Feb 2021

@IAM_Alerts Intellectual Ventures has rolled out a new licensing programme focused on Chinese SMEs. Details on pricing, terms a… https://t.co/nrCi3LEi10 Read more

25 Feb 2021

@IAM_Alerts Ericsson says Chinese court's anti-suit order amounts to 'forced technology transfer' - full details of the latest… https://t.co/rF2kr3kZ9a Read more

Find an expert

Partner

Washington DC, United States

Axinn, Veltrop & Harkrider LLP

View full biography